지니너스

389030KOSDAQ자연과학 및 공학 연구개발업

51.8 / 100

Reference Date: 2026-04-13

Financial Score10.5 / 40

News Sentiment21.3 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Declined 11.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Geninus focuses on genomics, bioinformatics, and the development of in-vitro diagnostic medical devices, leveraging advanced technologies such as NGS and PCR to provide innovative healthcare solutions in early cancer detection, liquid biopsy, and precision medicine. The company also conducts research on mutations and biomarkers to support disease prognosis prediction and personalized treatment strategies.

Number of Employees

59people

Average Salary

72.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

17.28Industry Average 3.820.0Point

4.5x industry avg (risky)

ROE

-110.87Industry Average -32.113.5Point

3.5x industry avg (excellent)

Debt Ratio

18.72Industry Average 7.520.0Point

2.5x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲27.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼8.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -59.7% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 85

Positive
지니너스, 日 대형 제약사 '러브콜'.. AI 신약 플랫폼 수출 본격화
지니너스의 일본 자회사 GxD가 현지 대형 제약사와 '인텔리메드' 기반 프로젝트 계약을 체결하며 AI 신약 플랫폼 수출을 본격화했습니다.
Positive
지니너스 인공지능 기반 신약 개발 플랫폼, 日 제약사 뚫었다
지니너스의 AI 기반 신약개발 플랫폼이 일본 대형 제약사와의 협력을 통해 일본 시장에 진출했습니다.
Positive
지니너스, 日대형 제약사와 인텔리메드 공급 계약
지니너스가 일본 자회사를 통해 현지 대형 제약사와 '인텔리메드' 공급 계약을 체결하며 장기 협력 가능성을 높였습니다.

Detailed Momentum

52-week position6.0Point

52w upper range (69%)

Current 4,705Won52-week high 6,27052-week low 1,151

1-month return1.0Point

1m -11.23% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

10 totalPositive 0Neutral 10Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-04-01
Neutral주식등의대량보유상황보고서(약식)2026-03-27
Neutral[기재정정]증권발행결과(자율공시)2026-03-26
Neutral[기재정정]증권발행결과(자율공시)2026-03-26
Neutral증권발행결과(자율공시)2026-03-25